<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006619</article-id><article-id pub-id-type="pmc">PMC11859816</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020252</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00252</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effects of Sex and Cross-Sex Hormone Treatment on Renal MCT/SMCT Expression Following Prepubertal Gonadectomy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-4563-4281</contrib-id><name><surname>Lee</surname><given-names>Annie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Hao</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Felmlee</surname><given-names>Melanie A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-pharmaceutics-17-00252" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ikeda</surname><given-names>Yasumasa</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00252">Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA; <email>a_lee82@u.pacific.edu</email> (A.L.); <email>q_zhang6@u.pacific.edu</email> (Q.Z.); <email>h_wei1@u.pacific.edu</email> (H.W.)</aff><author-notes><corresp id="c1-pharmaceutics-17-00252"><label>*</label>Correspondence: <email>mfelmlee@pacific.edu</email>; Tel.: +1-209-946-7417; Fax: +1-209-946-2410</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>252</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>01</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Kidney proton- and sodium-dependent monocarboxylate transporters (MCT/SMCT) are involved in the renal reabsorption of substrates, and thus factors involved in their regulation may have pharmacokinetic implications. Previous studies have demonstrated sex hormone-dependent regulation of MCTs and SMCTs in tissues involved in drug disposition. The present study evaluates the impact of puberty on renal MCT/SMCT expression with ovariectomy and castration conducted before puberty, removing the initial exposure to sex hormones. <bold>Methods:</bold> Male and female rats were castrated or ovariectomized before puberty (4 weeks of age), and subsequently treated with testosterone, 17&#x003b2;-estradiol, progesterone, or both 17&#x003b2;-estradiol and progesterone for 21 days starting at 10 weeks of age. MCT1, CD147, and SMCT1 membrane-bound kidney expression were quantified by Western blot. <bold>Results:</bold> SMCT1 and CD147 expression were significantly higher in OVX and CST rats treated with testosterone, and testosterone plasma concentrations showed a significant positive correlation with MCT1, SMCT1, and CD147 expression. CD147 expression was significantly downregulated in OVX rats treated with estrogen, compared to placebo controls, and estrogen plasma concentrations were significantly negatively correlated with CD147 expression. <bold>Conclusions:</bold> Sex and cross-sex hormone treatment altered MCT1, CD147, and SMCT1 expression when gonadectomy was conducted before puberty. The magnitude and direction of the expression differences differed when compared to animals that underwent gonadectomy after puberty, suggesting that sex hormone exposure during puberty plays a key role in MCT1/SMCT1 renal expression. Further studies are needed to elucidate the underlying mechanisms for the differential regulation of MCTs/SMCTs when gonadectomy occurs before or after puberty.</p></abstract><kwd-group><kwd>monocarboxylate transporters</kwd><kwd>sex hormones</kwd><kwd>testosterone</kwd><kwd>17&#x003b2;-estradiol</kwd><kwd>puberty</kwd></kwd-group><funding-group><award-group><funding-source>NIDA/NIGMS</funding-source><award-id>DA052120</award-id></award-group><funding-statement>This research was funded by NIDA/NIGMS grant number DA052120.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00252"><title>1. Introduction</title><p>The solute carrier 16 (SLC16) family is comprised of 14 monocarboxylate transporters (MCT1-14, SLC16A1-14), and the solute carrier 5A (SLC5A) family includes sodium-dependent monocarboxylate transporters SMCT1 (SLC5A8) and SMCT2 (SLC5A12) [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00252" ref-type="bibr">2</xref>]. MCTs depend on ancillary proteins for membrane expression [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>]. CD147 (basigin) is an ancillary protein for MCTs 1, 3, 4, 11, and 12, and has been demonstrated to mediate the translocation of MCT1 and MCT4 for cell surface expression [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>,<xref rid="B3-pharmaceutics-17-00252" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00252" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00252" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00252" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00252" ref-type="bibr">7</xref>]. Embigin (gp70) is an ancillary protein for MCT2, and functions as an alternate chaperone for MCT1 when CD147 is not present [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>,<xref rid="B3-pharmaceutics-17-00252" ref-type="bibr">3</xref>]. MCTs 1-4 and SMCT1 transport pyruvate, lactate, short-chain fatty acids, and monocarboxylate drugs [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00252" ref-type="bibr">2</xref>]. The other isoforms transport drugs such as probenecid and bumetanide (MCT6), ketone bodies (MCT 7), thyroid hormones T3 and T4 (MCT8), carnitine (MCT9), aromatic amino acids (MCT10), and creatinine (MCT12) [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>].</p><p>MCT/SMCTs are expressed throughout the body, but isoform expression is tissue-specific [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>]. At the proximal renal tubule, MCT1 and MCT4 are expressed on the basolateral membrane, while SMCT1 is localized to the apical membrane of the S2/S3 segments [<xref rid="B8-pharmaceutics-17-00252" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00252" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-17-00252" ref-type="bibr">10</xref>]. Kidney MCT/SMCTs mediate the renal reabsorption of exogenous drugs, including &#x003b3;-hydroxybutyrate (GHB). Consequently, renal monocarboxylate transporter expression has pharmacokinetic implications, as the kidney is a major organ for drug excretion. GHB pharmacokinetic studies revealed variability in renal clearance between females in different stages of the estrous cycle, ovariectomized (OVX) females, intact males, and castrated (CST) males [<xref rid="B11-pharmaceutics-17-00252" ref-type="bibr">11</xref>]. Proestrus females had significantly higher renal clearance than OVX females, CST males, intact males, and diestrus females following 600 mg/kg GHB i.v. [<xref rid="B11-pharmaceutics-17-00252" ref-type="bibr">11</xref>]. These results indicated sex hormone mediated differences in GHB toxicokinetics and renal clearance, which are likely attributable to sex hormone-dependent regulation of kidney MCT/SMCT expression [<xref rid="B11-pharmaceutics-17-00252" ref-type="bibr">11</xref>].</p><p>The effects of sex hormones on monocarboxylate transporter expression have been evaluated in hindlimb muscles [<xref rid="B12-pharmaceutics-17-00252" ref-type="bibr">12</xref>], heart [<xref rid="B12-pharmaceutics-17-00252" ref-type="bibr">12</xref>], and brain [<xref rid="B13-pharmaceutics-17-00252" ref-type="bibr">13</xref>], but there is limited kidney expression data [<xref rid="B14-pharmaceutics-17-00252" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00252" ref-type="bibr">15</xref>]. Kidney smct1 protein expression in orchiectomized mice was lower than in sham-operated mice, while testosterone-treated orchiectomized mice had greater expression compared to orchiectomized mice [<xref rid="B14-pharmaceutics-17-00252" ref-type="bibr">14</xref>]. Alternatively, ovariectomized (OVX) mice treated with progesterone had significantly lower kidney smct1 protein expression compared to OVX mice [<xref rid="B15-pharmaceutics-17-00252" ref-type="bibr">15</xref>]. We previously demonstrated sex hormone-mediated differences in MCT/SMCT protein expression in rats that underwent castration (CST) or OVX after the onset of puberty [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>]. MCT1 expression in OVX rats was downregulated with estrogen and progesterone treatment and upregulated with testosterone treatment. CD147 expression was significantly greater in OVX rats treated with testosterone, compared to corresponding placebo. SMCT1 expression in CST rats was upregulated with estrogen, alone or in combination with progesterone, and downregulated with testosterone treatment. However, the role of the initial pubertal hormone exposure and the underlying regulatory mechanisms on the observed expression differences is unknown. Pubertal hormone exposure plays a vital role in the development of sex differences and has been demonstrated to impact epigenetic regulatory mechanisms, specifically, DNA methylation [<xref rid="B17-pharmaceutics-17-00252" ref-type="bibr">17</xref>]. MCT1 regulation by DNA methylation has been demonstrated, and this may lead to differences in responses to exogenous sex hormones when gonadectomy is conducted before puberty.</p><p>The aim herein is to evaluate MCT/SMCT renal expression in response to sex and cross-sex hormone treatment in animals that have not gone through puberty, in order to evaluate the role of puberty in MCT/SMCT regulation. Renal membrane MCT1, CD147, and SMCT1 expression were evaluated in animal models that had undergone gonadectomy at a prepubescent age of 4 weeks [<xref rid="B18-pharmaceutics-17-00252" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00252" ref-type="bibr">19</xref>] with subsequent hormone replacement with testosterone, 17&#x003b2;-estradiol, progesterone, or both 17&#x003b2;-estradiol and progesterone (or their respective placebo pellets).</p></sec><sec id="sec2-pharmaceutics-17-00252"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00252"><title>2.1. Chemicals</title><p>LC/MS-grade acetonitrile was purchased from Fisher Scientific (Waltham, MA, USA). Testosterone-d3 and progesterone-d9 were obtained from Cerilliant (Round Rock, TX, USA). Ketamine, xylazine, and heparin were procured from Patterson Veterinary (Rocky Mountain, CO, USA).</p></sec><sec id="sec2dot2-pharmaceutics-17-00252"><title>2.2. Animals, Hormone Implantation, and Tissue Collection</title><p>OVX female and CST male Sprague&#x02013;Dawley (SD) rats were procured from Charles River (Wilmington, MA, USA) at 5 weeks of age. Castration and ovariectomy surgeries were performed at 4 weeks of age at Charles River. Intact male and female Sprague&#x02013;Dawley rats were procured from Charles River (Wilmington, MA, USA) at 8 weeks of age. Rats were housed in a temperature- and humidity-controlled environment with an alternating 12 h light/dark cycle and ad libitum access to rat chow and water. The Institutional Animal Care and Use Committee at the University of the Pacific approved all animal research conducted.</p><p>At 10 weeks of age, rats were subcutaneously implanted with a hormone pellet(s) in the region of the left shoulder blade, under isoflurane anesthesia. The pellets contained 1.5 mg 17&#x003b2;-estradiol and/or 50 mg progesterone, or 7.5 mg testosterone, or respective placebos formulated to release over 60 days (N = 6 per treatment group). The rats were exsanguinated and the tissue was collected under isoflurane anesthesia following 21 days of hormone exposure. Kidney samples were also collected from age-matched intact males and females in the estrus stage. Estrous cycles were monitored prior to tissue collection, using vaginal cytology methods described previously [<xref rid="B11-pharmaceutics-17-00252" ref-type="bibr">11</xref>,<xref rid="B20-pharmaceutics-17-00252" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00252" ref-type="bibr">21</xref>]. Kidneys were snap-frozen in liquid nitrogen and stored at &#x02212;80 &#x000b0;C for subsequent experiments. Heparinized blood was centrifuged at 5000 rcf for 15 min at 4 &#x000b0;C to attain plasma; the samples were stored at &#x02212;20 &#x000b0;C until further analysis.</p></sec><sec id="sec2dot3-pharmaceutics-17-00252"><title>2.3. Quantifications of Plasma Estrogen, Progesterone, and Testosterone</title><p>Plasma progesterone and testosterone concentrations were simultaneously measured using a previously validated LC-MS method, with minor modifications [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>,<xref rid="B22-pharmaceutics-17-00252" ref-type="bibr">22</xref>]. Briefly, standard and quality control (QC) stock solutions were prepared by diluting 200 &#x000b5;g/mL of the Steroids and Mixed Pharmaceutical Mix (Restek Corporation, Bellefonte, PA, USA) with acetonitrile. Standard and QC samples were prepared with 10 &#x000b5;L stock, 90 &#x000b5;L acetonitrile, 5 &#x000b5;L 100 ng/mL progesterone-d9, and 5 &#x000b5;L 100 ng/mL testosterone-d3. Plasma samples were prepared with 100 &#x000b5;L samples (or diluted with acetonitrile to be within the calibration range) of 5 &#x000b5;L 100 ng/mL progesterone-d9 and 5 &#x000b5;L 100 ng/mL testosterone-d3. Additionally, 1 mL of acetonitrile was added to each sample to precipitate proteins, and samples were centrifuged at 10,000 rpm for 20 min. In sum, 950 &#x000b5;L of supernatant was aspirated, dried under a stream of nitrogen, and reconstituted with 200 &#x000b5;L acetonitrile. The samples were analyzed with an Agilent 1200 series UPLC with an online degasser, binary pump, and autosampler coupled to an Agilent 6460 Triple Quad Mass Spectrometer. The chromatographic and MS conditions used were reported in a previous publication [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>].</p><p>Plasma 17&#x003b2;-estradiol concentrations were measured with a competitive ELISA kit (Abcam, Cambridge, UK) in accordance with the manufacturer&#x02019;s protocol. The concentrations were interpolated from the calibration curve using GraphPad Prism 10.3.1 (San Diego, CA, USA). Inter- and intra-day accuracy and precision based on quality control samples of the analyte were between 80 to 120%.</p></sec><sec id="sec2dot4-pharmaceutics-17-00252"><title>2.4. Western Blot</title><p>Kidney soluble and membrane protein fractions were extracted with the ProteoExtract Native Membrane Extraction kit (MilliporeSigma, Burlington, MA, USA). Total protein concentrations were determined with the Pierce BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA, USA). Samples were diluted with deionized water and 4X Laemmli Sample buffer (BioRad, Hercules, CA, USA) containing 2-Mercaptoethanol (&#x003b2;ME). Samples were heated at 37 &#x000b0;C for 30 min and 5 &#x000b5;g of protein was loaded into each lane for separation at 200 V on TGX Stain-Free FastCast Acrylamide 10% gels (BioRad, Hercules, CA, USA). Proteins were transferred to Odyssey Nitrocellulose Membranes (LI-COR, Lincoln, NE, USA) at 100 V for 25 min. Blots for SMCT1 analyses were cut above/at 100 MW and below 25 MW prior to blocking due to the presence of nonspecific binding. Membranes were blocked with 5% milk in 1X PBST for 1 or 1.5 h under rotation at room temperature prior to incubation with primary antibody for 15 to 16 h at 4 &#x000b0;C. The primary antibodies used for semi-quantification were anti-MCT1 (AB3540P, MilliporeSigma, Burlington, MA, USA), anti-CD147 (OAAJ01996, AVIVA, San Diego, CA, USA), and anti-SMCT1 (ARP44110_P050, AVIVA, San Diego, CA), and ATP1A1/ATP1A2/ATP1A3 (H-3) (sc-48345, Santa Cruz, Dallas, TX, USA) was used for validation; the antibodies were diluted with 1% milk in 1X PBST at 1:1350 for anti-MCT1 and at 1:1000 for the other antibodies. The membranes were washed with 1X PBST (3 to 4 times, 10 min each) before and after incubation with the secondary antibody. Membranes were incubated with secondary antibodies for 1 h at room temperature; goat anti-rabbit IgG H&#x00026;L(HRP) (ab97051, abcam, Cambridge, UK) diluted at 1:10,000 was used for MCT1 analysis, and peroxidase AffiniPure goat anti-rabbit IgG (111-035-144, Jackson ImmunoResearch, West Grove, PA, USA) was diluted at 1:5000 for CD147 analysis and at 1:10,000 for SMCT1 analysis. The membranes were incubated with Clarity ECL reagent (BioRad, Hercules, CA, USA) for 2 min; SMCT1 blots were incubated with Radiance Plus Femtogram HRP substrate (Azure, Dublin, CA, USA) for 3 min. The chemiluminescent bands were imaged with a ChemidocTM Touch Imaging System (BioRad, Hercules, CA, USA). Band density and total lane density were determined with BioRad Image 6.0.1 software.</p></sec><sec id="sec2dot5-pharmaceutics-17-00252"><title>2.5. Data Analysis</title><p>Results are presented as mean &#x000b1; standard deviation (SD) with individual data points. Individual protein band densities were normalized to total lane densities and adjusted using the inter-blot control to account for loading variability and variation across blots. Analyses were performed with GraphPad Prism 10.3.1 (San Diego, CA, USA). For each target protein and hormone treatment (testosterone, 17&#x003b2;-estradiol, progesterone, or 17&#x003b2;-estradiol and progesterone combined), mean density values of hormone-treated, hormone placebo-treated, and male and female controls were compared using one-way analysis of variance (ANOVA) with a Tukey post hoc test; <italic toggle="yes">p</italic>-values &#x0003c; 0.05 were considered significant. Differences between intact male and female controls were analyzed with an unpaired <italic toggle="yes">t</italic>-test; <italic toggle="yes">p</italic>-values &#x0003c; 0.05 were considered significant. Pearson correlation analyses between plasma sex hormone levels and protein expression and correlation analysis between MCT1 and CD147 expression were conducted with GraphPad Prism 10.3.1 (San Diego, CA, USA).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00252"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00252"><title>3.1. Plasma Sex Hormone Concentrations</title><p>Plasma sex hormone concentrations are reported in <xref rid="pharmaceutics-17-00252-t001" ref-type="table">Table 1</xref>. OVX and CST estrogen-, progesterone-, and combination-treated rats had higher plasma sex hormone concentrations than respective placebo groups. Plasma testosterone concentrations for OVX and CST testosterone rats were 6.01 &#x000b1; 2.237 and 5.832 &#x000b1; 1.8 ng/mL, respectively. Testosterone was undetected in OVX and CST rats treated with female sex hormones or placebo hormone pellets. Female control rats had greater plasma 17&#x003b2;-estradiol and progesterone levels than male controls, and undetectable testosterone levels. 17&#x003b2;-estradiol, progesterone, and testosterone concentrations in hormone- and placebo-treated rats, as well as intact male and female controls, were consistent with those observed following hormone treatment in age-matched post-puberty OVX and CST animals [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>].</p></sec><sec id="sec3dot2-pharmaceutics-17-00252"><title>3.2. MCT1 Expression</title><p>MCT1 membrane expression and treatment differences are presented in <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref> and <xref rid="pharmaceutics-17-00252-t002" ref-type="table">Table 2</xref>. MCT1 membrane expression was significantly different across groups (<italic toggle="yes">p</italic> = 0.0002: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>A, <italic toggle="yes">p</italic> = 0.0001: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>B, <italic toggle="yes">p</italic> = 0.0006: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>C, <italic toggle="yes">p</italic> = 0.0002: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>D, <italic toggle="yes">p</italic> = 0.0004: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>E, <italic toggle="yes">p</italic> = 0.0001: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>F, <italic toggle="yes">p</italic> = 0.0007: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>G, and <italic toggle="yes">p</italic> = 0.0023: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>H). The OVX combo trended lower compared to OVX combo placebo (<italic toggle="yes">p</italic> = 0.6262, <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>E), while OVX/CST testosterone groups trended higher than their respective placebo groups (<italic toggle="yes">p</italic> = 0.8550: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>G; <italic toggle="yes">p</italic> = 0.1618: <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>H). No significant differences in MCT1 expression were observed between the hormone-treated and hormone placebo groups. Intact females and OVX/CST groups treated with estrogen and/or progesterone, or their respective placebos, had significantly lower expression than intact males (<xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>A&#x02013;F). Additionally, OVX testosterone, OVX testosterone placebo, and CST testosterone placebo groups had significantly lower expression than intact males (<italic toggle="yes">p</italic> = 0.0039 and <italic toggle="yes">p</italic> = 0.006, <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>G; <italic toggle="yes">p</italic> = 0.0011, <xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>H).</p></sec><sec id="sec3dot3-pharmaceutics-17-00252"><title>3.3. CD147 Expression</title><p>CD147 membrane expression and treatment differences are presented in <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref> and <xref rid="pharmaceutics-17-00252-t002" ref-type="table">Table 2</xref>. CD147 membrane expression was significantly different across OVX groups (<italic toggle="yes">p</italic> = 0.01: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>A, <italic toggle="yes">p</italic> = 0.05: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>C, and <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>G). OVX estrogen-treated rats had significantly lower CD147 expression compared to OVX estrogen placebo (<italic toggle="yes">p</italic> = 0.0116, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>C). OVX progesterone-treated rats trended higher than OVX progesterone placebo; however, these differences were not statistically significant (<italic toggle="yes">p</italic> = 0.0735, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>C). OVX testosterone rats had significantly greater expression than OVX testosterone placebo (<italic toggle="yes">p</italic> = 0.0009, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>G). Additionally, OVX testosterone rats had significantly greater expression than both intact females (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>G) and intact males (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>G).</p><p>CD147 membrane expression was significantly different across CST groups (<italic toggle="yes">p</italic> = 0.0141: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>D, <italic toggle="yes">p</italic> = 0.0387: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>F, and <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>H), with the exception of CST estrogen-treated animals (<italic toggle="yes">p</italic> = 0.0654, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>B). CST testosterone-treated rats had significantly greater expression than CST testosterone placebo (<italic toggle="yes">p</italic> = 0.0004, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>H). CST testosterone-treated rats had significantly greater expression than both intact males (<italic toggle="yes">p</italic> = 0.0001, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>H) and intact females (<italic toggle="yes">p</italic> = 0.0004, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>H). CST combo rats trended modestly lower compared to CST combo placebo (<italic toggle="yes">p</italic> = 0.1918, <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>F); however, no significant difference in CD147 expression was observed between female sex hormone-treated rats and their respective placebo groups. CST estrogen placebo, CST progesterone placebo, and CST combo placebo groups had significantly higher expression compared to intact males (<italic toggle="yes">p</italic> = 0.041: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>B, <italic toggle="yes">p</italic> = 0.0210: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>D, and <italic toggle="yes">p</italic> = 0.0255: <xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>F).</p></sec><sec id="sec3dot4-pharmaceutics-17-00252"><title>3.4. SMCT1 Expression</title><p>SMCT1 membrane expression and treatment differences are presented in <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref> and <xref rid="pharmaceutics-17-00252-t002" ref-type="table">Table 2</xref>. SMCT1 membrane expression was significantly different across OVX groups (<italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>A, <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>C, <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>E, and <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>G). OVX testosterone-treated rats had significantly greater expression compared to OVX testosterone placebo (<italic toggle="yes">p</italic> = 0.0005, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>G). OVX estrogen and placebo groups had significantly lower expression than intact females (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>A). OVX progesterone and progesterone placebo groups had significantly reduced expression compared to both female (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>C) and male controls (<italic toggle="yes">p</italic> = 0.0057 and <italic toggle="yes">p</italic> = 0.0005, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>C). OVX combo and combo placebo groups had significantly lower expression than intact females (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>E). OVX testosterone had significantly lower expression than intact females (<italic toggle="yes">p</italic> = 0.0002, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>G) and OVX testosterone placebo had significantly reduced expression compared to both intact female (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>G) and male controls (<italic toggle="yes">p</italic> = 0.0075, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>G). Intact females had significantly greater expression, compared to intact males (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>A&#x02013;G).</p><p>SMCT1 membrane expression was significantly different across CST groups (<italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>B, <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>D, <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>F, and <italic toggle="yes">p</italic> &#x0003c; 0.0001: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>H). CST testosterone-treated rats had significantly greater expression compared to CST testosterone placebo (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>H). CST testosterone had significantly lower expression than intact females (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>H) and CST testosterone placebo had significantly reduced expression compared to both intact females (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>H) and intact males (<italic toggle="yes">p</italic> = 0.0079, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>H). CST estrogen and CST combo rats trended modestly higher compared to their respective placebo groups (<italic toggle="yes">p</italic> = 0.1098: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>B, <italic toggle="yes">p</italic> = 0.0959: <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>F). CST estrogen and respective placebo groups had significantly lower expression than intact females (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>B). CST progesterone and progesterone placebo groups had significantly reduced expression compared to both female (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>D) and male controls (<italic toggle="yes">p</italic> = 0.0005, <italic toggle="yes">p</italic> = 0.0124, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>D). CST combo and corresponding placebo groups had significantly lower expression than intact females (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>H).</p></sec><sec id="sec3dot5-pharmaceutics-17-00252"><title>3.5. Correlation Analysis</title><p>Pearson correlation analyses are presented in <xref rid="app1-pharmaceutics-17-00252" ref-type="app">Supplementary Figures S1&#x02013;S4</xref>. MCT1 membrane expression was positively correlated (r = 0.2416) with CD147 expression (<italic toggle="yes">p</italic> = 0.0118, <xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S1</xref>). MCT1 expression was positively correlated (r = 0.2944) with testosterone concentrations (<italic toggle="yes">p</italic> = 0.0036, <xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S4</xref>). No significant correlations were observed for female sex hormones and MCT1 expression. CD147 expression was negatively correlated (r = &#x02212;0.2344) with plasma 17&#x003b2;-estradiol levels (<italic toggle="yes">p</italic> = 0.0215, <xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S2</xref>) and positively correlated (r = 0.6207) with testosterone levels (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S4</xref>). SMCT1 expression was positively correlated (r = 0.3785) with plasma testosterone (<italic toggle="yes">p</italic> = 0.0001, <xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S4</xref>). All evaluated target proteins had no significant correlation with progesterone levels (<xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S3</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00252"><title>4. Discussion</title><p>Differences in monocarboxylate transporter expression can alter the renal clearance of substrates. We have previously demonstrated changes in &#x003b3;-hydroxybutyrate (GHB) toxicokinetics and renal clearance with testosterone treatment [<xref rid="B23-pharmaceutics-17-00252" ref-type="bibr">23</xref>] and changes in renal MCT/SMCT expression following sex and cross-sex hormone treatment in rats that underwent gonadectomy after the onset of puberty [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>]. In the present study, prepubertal ovariectomy and castration was conducted to evaluate sex and cross-sex hormone-driven regulation in the absence of initial pubertal hormone exposure. 17&#x003b2;-estradiol-, progesterone-, and testosterone-mediated changes in renal MCT1, CD147, and SMCT1 membrane protein expression were observed in rats with ovariectomy and castration before the onset of puberty.</p><p>Treatment with estrogen, progesterone, or testosterone did not significantly alter MCT1 expression when OVX and CST occurred before the onset of puberty (<xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>A&#x02013;H); MCT1 expression trended lower in OVX rats treated with a combination of estrogen and progesterone (<xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>E). These data are consistent with post-puberty studies, in which 17&#x003b2;-estradiol or progesterone alone did not significantly downregulate expression, but OVX rats treated with 17&#x003b2;-estradiol and progesterone combined had significantly reduced expression compared to placebo [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>]. However, in contrast to post-puberty gonadectomy, no significant negative correlations between MCT1 expression and plasma 17&#x003b2;-estradiol concentrations were observed in the present study (<xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S1</xref>). Altogether, the results suggest that downregulation of MCT1 expression in rats OVX before and after puberty requires both estrogen and progesterone, but the effects of female sex hormones may be reduced when ovariectomy occurs prepubertally. A similar diminished effect when compared to post-puberty studies was observed with testosterone treatment. MCT1 expression trended higher in OVX and CST rats treated with testosterone compared to their respective placebo controls (<xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>G,H), and MCT1 expression demonstrated a significant positive correlation with testosterone plasma concentration (<xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S3</xref>). This testosterone-mediated effect is consistent with the significantly greater MCT1 expression observed in intact males relative to intact females (<xref rid="pharmaceutics-17-00252-g001" ref-type="fig">Figure 1</xref>A). OVX rats treated with testosterone had significantly greater expression compared to both placebo-treated and intact males [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>]. The trend of testosterone-driven upregulation of MCT1 expression was observed in rats OVX before and after the onset of puberty. However, following testosterone treatment, rats OVX before puberty had a reduced percent change in MCT1 expression compared to rats OVX post puberty. The decreased change in expression suggests the absence of initial exposure to pubertal hormones diminishes the effect of testosterone on MCT1 upregulation in OVX rats.</p><p>CD147 functions as the ancillary protein for MCT1, and the association of the two proteins enhances MCT1 membrane expression [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>,<xref rid="B5-pharmaceutics-17-00252" ref-type="bibr">5</xref>]. Testosterone treatment altered CD147 expression in rats that underwent OVX and CST prior to puberty (<xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>G,H), while estrogen treatment altered expression in OVX alone (<xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>A). CD147 expression displayed a significant positive correlation with plasma testosterone concentrations (<xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S3</xref>) and a significant negative correlation with plasma 17&#x003b2;-estradiol levels (<xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S1</xref>), consistent with the observed trends in protein expression. CD147 membrane expression in OVX rats treated with estrogen was significantly reduced compared to placebo controls (<xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>A), suggesting estrogen is involved in the downregulation of CD147 in OVX rats; however, this difference in CD147 expression was not exhibited in rats that underwent OVX post-puberty [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>]. This suggests a more pronounced effect of estrogen treatment alone in rats that have not gone through puberty. Additionally, both OVX and CST rats treated with testosterone had significantly greater expression than the respective placebo groups (<xref rid="pharmaceutics-17-00252-g002" ref-type="fig">Figure 2</xref>G,H), demonstrating that testosterone mediated upregulation of CD147 expression following both sex- and cross-sex treatment. When OVX occurred after puberty, testosterone treatment resulted in a significant increase in expression, compared to the OVX placebo group [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>], consistent with prepuberty results. In contrast, no significant difference was observed, when CST occurred post-puberty, between CST rats treated with testosterone and those treated with placebo [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>], indicating differential effects of testosterone in rats CST pre- and post-puberty.</p><p>SMCT1 expression was significantly upregulated in response to sex- and cross-sex testosterone treatment in rats with OVX and CST before puberty (<xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>G,H) and demonstrated a significant positive correlation with plasma testosterone concentrations (<xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figure S3</xref>). Testosterone treatment had a differential effect when OVX and CST occurred after puberty, with significantly downregulated expression in CST rats treated with testosterone compared placebo-treated animals, while OVX rats had modestly higher expression versus placebo [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>]. Taken together, the results suggest testosterone has differential effects when CST occurs before or after puberty, with a significant upregulation observed in prepuberty studies and significant downregulation observed in post-puberty evaluations. Hosoyamada et al. investigated the contribution of androgens to hyperuricemia; smct1 was evaluated due to its role in urate reabsorption [<xref rid="B14-pharmaceutics-17-00252" ref-type="bibr">14</xref>]. Testosterone upregulated kidney smct1 expression in orchiectomized mice [<xref rid="B14-pharmaceutics-17-00252" ref-type="bibr">14</xref>], consistent with the presently observed effects of testosterone. SMCT1 membrane expression was not significantly different between CST rats treated with female sex hormones and those treated with the respective placebo controls (<xref rid="pharmaceutics-17-00252-g003" ref-type="fig">Figure 3</xref>A&#x02013;F), and no significant positive correlations were observed with 17&#x003b2;-estradiol or progesterone plasma concentrations (<xref rid="app1-pharmaceutics-17-00252" ref-type="app">Figures S2 and S3</xref>), in contrast to the post-puberty studies. When CST occurred after puberty, estrogen treatment significantly increased SMCT1 expression compared to placebo, and treatment with estrogen and progesterone combined significantly increased expression as compared to placebo [<xref rid="B16-pharmaceutics-17-00252" ref-type="bibr">16</xref>]. SMCT1 expression is upregulated following cross-sex female hormone treatment when gonadectomy occurs after puberty, but is unaltered when gonadectomy occurs before puberty, demonstrating the impact of puberty on estrogen/progesterone-mediated regulation of SMCT1.</p><p>Testosterone treatment altered the toxicokinetics of GHB (an MCT/SMCT substrate) in rats that underwent OVX and CST surgery after puberty [<xref rid="B23-pharmaceutics-17-00252" ref-type="bibr">23</xref>]. Following i.v. administration of 1500 mg/kg GHB, plasma exposure (AUC) was significantly increased in CST rats treated with testosterone, compared to placebo [<xref rid="B23-pharmaceutics-17-00252" ref-type="bibr">23</xref>]. Additionally, the fraction of drug eliminated in urine (fe) was significantly decreased in the OVX and CST rats treated with testosterone, compared to the respective placebo controls [<xref rid="B23-pharmaceutics-17-00252" ref-type="bibr">23</xref>]. These observed differences are consistent with the testosterone-mediated upregulation of renal MCT1 expression seen in rats CST or OVX after puberty. Future toxicokinetic studies should be conducted in rats that have undergone gonadectomy before puberty to determine the implications of the observed differences in MCT and SMCT regulation on GHB toxicokinetics and toxicity.</p><p>Future studies should evaluate the underlying mechanisms contributing to the observed differences in expression when gonadectomy is performed before or after puberty. Epigenetic regulation of MCT/SMCT expression has been evaluated in the scope of disease states [<xref rid="B1-pharmaceutics-17-00252" ref-type="bibr">1</xref>], and represents a potential mechanism for the expression differences observed in the present study. Epigenetic regulation via DNA methylation of CpG sites has been demonstrated to influence MCT gene expression [<xref rid="B24-pharmaceutics-17-00252" ref-type="bibr">24</xref>]. MCT1 gene expression was downregulated and upregulated in the breast cancer cell line MDA-MB-231 with CpG island methylation and 5-aza-2&#x02019;-deoxycytidine-induced demethylation, respectively [<xref rid="B24-pharmaceutics-17-00252" ref-type="bibr">24</xref>]. The effects of puberty and exogenous hormone administration on global epigenetic regulation have been investigated [<xref rid="B17-pharmaceutics-17-00252" ref-type="bibr">17</xref>,<xref rid="B25-pharmaceutics-17-00252" ref-type="bibr">25</xref>], but to our knowledge, there are no studies evaluating the effect of sex hormones on DNA methylation of CpG sites associated with MCT or SMCT gene expression. Han et al. demonstrated differences pre- and post-adolescence in the methylation of 15,532 CpG sites [<xref rid="B17-pharmaceutics-17-00252" ref-type="bibr">17</xref>]. Additionally, female participants who were on oral contraceptives had an overall reduced global DNA methylation compared to participants who did not utilize contraceptives [<xref rid="B25-pharmaceutics-17-00252" ref-type="bibr">25</xref>]. Future studies will assess DNA methylation and sex hormone regulation of MCT1/SMCT1 in human cells to evaluate the translatability of these regulatory mechanisms to the human population.</p><p>In summary, sex and cross-sex hormone-induced differences in MCT1, CD147, and SMCT1 expression were observed when gonadectomy was conducted before puberty. The presence or absence of expression differences, as well as the directionality of change relative to expression data, in animals that had undergone gonadectomy after puberty differed based on target protein and sex hormone treatment. MCT1 analysis demonstrated a reduced or absent effect of sex hormones on expression, whereas CD147 results demonstrated a retained effect of testosterone upregulation of expression. SMCT1 results showed a differential effect of testosterone on membrane-bound expression, with significant upregulation when gonadectomy occurred before puberty, and with downregulation observed with post-puberty gonadectomy. Additional investigations are necessary to understand the mechanisms responsible for these observed differences when gonadectomy occurs before or after puberty, and the consequences of MCT/SMCT expression differences on the renal clearance of drug substrates.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Tori Matthews for her assistance with the completion of the tissue collection studies.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-00252"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17020252/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17020252/s1</uri>. Figure S1: Pearson correlation between MCT1 and CD147. Figure S2: Pearson correlation between MCT1, CD147, and SMCT1 expression and plasma 17&#x003b2;-estradiol concentrations. Figure S3: Pearson correlation between MCT1, CD147, and SMCT1 expression and plasma progesterone concentrations. Figure S4: Pearson correlation between MCT1, CD147, and SMCT1 expression and plasma testosterone concentrations. Figure S5: Western blot images of renal MCT1, CD147, and SMCT1 membrane expression. Figure S6: Stain-free blot images of total protein densities used for data normalization.</p><supplementary-material id="pharmaceutics-17-00252-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-17-00252-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, M.A.F.; Methodology, A.L., H.W., Q.Z. and M.A.F.; Validation, A.L., H.W. and M.A.F.; Formal Analysis, A.L. and M.A.F.; Investigation, A.L. and Q.Z.; Data Curation, A.L. and Q.Z.; Writing&#x02014;Original Draft Preparation, A.L.; Writing&#x02014;Review and Editing, A.L., Q.Z., H.W. and M.A.F.; Visualization, A.L. and M.A.F.; Supervision, M.A.F.; Project Administration, M.A.F.; Funding Acquisition, M.A.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Institutional Animal Care and Use of Committee (IACUC) of University of the Pacific (Protocol No.19R06 (approved 08/2019) and 22R06 (approved 11/2022)).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available within the article and <xref rid="app1-pharmaceutics-17-00252" ref-type="app">Supplementary Material</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00252"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Felmlee</surname><given-names>M.A.</given-names></name>
<name><surname>Jones</surname><given-names>R.S.</given-names></name>
<name><surname>Rodriguez-Cruz</surname><given-names>V.</given-names></name>
<name><surname>Follman</surname><given-names>K.E.</given-names></name>
<name><surname>Morris</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease</article-title><source>Pharmacol. Rev.</source><year>2020</year><volume>72</volume><fpage>466</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1124/pr.119.018762</pub-id><pub-id pub-id-type="pmid">32144120</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00252"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ganapathy</surname><given-names>V.</given-names></name>
<name><surname>Thangaraju</surname><given-names>M.</given-names></name>
<name><surname>Gopal</surname><given-names>E.</given-names></name>
<name><surname>Martin</surname><given-names>P.M.</given-names></name>
<name><surname>Itagaki</surname><given-names>S.</given-names></name>
<name><surname>Miyauchi</surname><given-names>S.</given-names></name>
<name><surname>Prasad</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Sodium-coupled monocarboxylate transporters in normal tissues and in cancer</article-title><source>Aaps J.</source><year>2008</year><volume>10</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1208/s12248-008-9022-y</pub-id><pub-id pub-id-type="pmid">18446519</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00252"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>M.C.</given-names></name>
<name><surname>Meredith</surname><given-names>D.</given-names></name>
<name><surname>Fox</surname><given-names>J.E.</given-names></name>
<name><surname>Manoharan</surname><given-names>C.</given-names></name>
<name><surname>Davies</surname><given-names>A.J.</given-names></name>
<name><surname>Halestrap</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: The ancillary protein for the insensitive MCT2 is EMBIGIN (gp70)</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>27213</fpage><lpage>27221</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411950200</pub-id><pub-id pub-id-type="pmid">15917240</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00252"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castorino</surname><given-names>J.J.</given-names></name>
<name><surname>Deborde</surname><given-names>S.</given-names></name>
<name><surname>Deora</surname><given-names>A.</given-names></name>
<name><surname>Schreiner</surname><given-names>R.</given-names></name>
<name><surname>Gallagher-Colombo</surname><given-names>S.M.</given-names></name>
<name><surname>Rodriguez-Boulan</surname><given-names>E.</given-names></name>
<name><surname>Philp</surname><given-names>N.J.</given-names></name>
</person-group><article-title>Basolateral sorting signals regulating tissue-specific polarity of heteromeric monocarboxylate transporters in epithelia</article-title><source>Traffic</source><year>2011</year><volume>12</volume><fpage>483</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2010.01155.x</pub-id><pub-id pub-id-type="pmid">21199217</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00252"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirk</surname><given-names>P.</given-names></name>
<name><surname>Wilson</surname><given-names>M.C.</given-names></name>
<name><surname>Heddle</surname><given-names>C.</given-names></name>
<name><surname>Brown</surname><given-names>M.H.</given-names></name>
<name><surname>Barclay</surname><given-names>A.N.</given-names></name>
<name><surname>Halestrap</surname><given-names>A.P.</given-names></name>
</person-group><article-title>CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression</article-title><source>Embo J.</source><year>2000</year><volume>19</volume><fpage>3896</fpage><lpage>3904</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.15.3896</pub-id><pub-id pub-id-type="pmid">10921872</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00252"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rusu</surname><given-names>V.</given-names></name>
<name><surname>Hoch</surname><given-names>E.</given-names></name>
<name><surname>Mercader</surname><given-names>J.M.</given-names></name>
<name><surname>Tenen</surname><given-names>D.E.</given-names></name>
<name><surname>Gymrek</surname><given-names>M.</given-names></name>
<name><surname>Hartigan</surname><given-names>C.R.</given-names></name>
<name><surname>DeRan</surname><given-names>M.</given-names></name>
<name><surname>von Grotthuss</surname><given-names>M.</given-names></name>
<name><surname>Fontanillas</surname><given-names>P.</given-names></name>
<name><surname>Spooner</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Type 2 Diabetes Variants Disrupt Function of SLC16A11 Through Two Distinct Mechanisms</article-title><source>Cell</source><year>2017</year><volume>170</volume><fpage>199</fpage><lpage>212.e120</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.011</pub-id><pub-id pub-id-type="pmid">28666119</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00252"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castorino</surname><given-names>J.J.</given-names></name>
<name><surname>Gallagher-Colombo</surname><given-names>S.M.</given-names></name>
<name><surname>Levin</surname><given-names>A.V.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>P.G.</given-names></name>
<name><surname>Polishook</surname><given-names>J.</given-names></name>
<name><surname>Kloeckener-Gruissem</surname><given-names>B.</given-names></name>
<name><surname>Ostertag</surname><given-names>E.</given-names></name>
<name><surname>Philp</surname><given-names>N.J.</given-names></name>
</person-group><article-title>Juvenile cataract-associated mutation of solute carrier SLC16A12 impairs trafficking of the protein to the plasma membrane</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2011</year><volume>52</volume><fpage>6774</fpage><lpage>6784</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-6579</pub-id><pub-id pub-id-type="pmid">21778275</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00252"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gopal</surname><given-names>E.</given-names></name>
<name><surname>Umapathy</surname><given-names>N.S.</given-names></name>
<name><surname>Martin</surname><given-names>P.M.</given-names></name>
<name><surname>Ananth</surname><given-names>S.</given-names></name>
<name><surname>Gnana-Prakasam</surname><given-names>J.P.</given-names></name>
<name><surname>Becker</surname><given-names>H.</given-names></name>
<name><surname>Wagner</surname><given-names>C.A.</given-names></name>
<name><surname>Ganapathy</surname><given-names>V.</given-names></name>
<name><surname>Prasad</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney</article-title><source>Biochim. Biophys. Acta</source><year>2007</year><volume>1768</volume><fpage>2690</fpage><lpage>2697</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.06.031</pub-id><pub-id pub-id-type="pmid">17692818</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00252"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>C.K.</given-names></name>
<name><surname>Brown</surname><given-names>M.S.</given-names></name>
<name><surname>Pathak</surname><given-names>R.K.</given-names></name>
<name><surname>Goldstein</surname><given-names>J.L.</given-names></name>
</person-group><article-title>cDNA cloning of MCT2, a second monocarboxylate transporter expressed in different cells than MCT1</article-title><source>J. Biol. Chem.</source><year>1995</year><volume>270</volume><fpage>1843</fpage><lpage>1849</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.4.1843</pub-id><pub-id pub-id-type="pmid">7829520</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00252"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deora</surname><given-names>A.A.</given-names></name>
<name><surname>Philp</surname><given-names>N.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Bok</surname><given-names>D.</given-names></name>
<name><surname>Rodriguez-Boulan</surname><given-names>E.</given-names></name>
</person-group><article-title>Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>16245</fpage><lpage>16250</lpage><pub-id pub-id-type="doi">10.1073/pnas.0504419102</pub-id><pub-id pub-id-type="pmid">16260747</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00252"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>J.</given-names></name>
<name><surname>Fallert</surname><given-names>T.</given-names></name>
<name><surname>Yeo</surname><given-names>S.</given-names></name>
<name><surname>Felmlee</surname><given-names>M.A.</given-names></name>
</person-group><article-title>GHB toxicokinetics and renal monocarboxylate transporter expression are influenced by the estrus cycle in rats</article-title><source>BMC Pharmacol. Toxicol.</source><year>2023</year><volume>24</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s40360-023-00700-y</pub-id><pub-id pub-id-type="pmid">37919807</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00252"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Enoki</surname><given-names>T.</given-names></name>
<name><surname>Yoshida</surname><given-names>Y.</given-names></name>
<name><surname>Lally</surname><given-names>J.</given-names></name>
<name><surname>Hatta</surname><given-names>H.</given-names></name>
<name><surname>Bonen</surname><given-names>A.</given-names></name>
</person-group><article-title>Testosterone increases lactate transport, monocarboxylate transporter (MCT) 1 and MCT4 in rat skeletal muscle</article-title><source>J. Physiol.</source><year>2006</year><volume>577</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2006.115436</pub-id><pub-id pub-id-type="pmid">16959859</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00252"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pyo</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Hwang</surname><given-names>J.</given-names></name>
<name><surname>Heo</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Cho</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Environmental Enrichment and Estrogen Upregulate Beta-Hydroxybutyrate Underlying Functional Improvement</article-title><source>Front. Mol. Neurosci.</source><year>2022</year><volume>15</volume><fpage>869799</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2022.869799</pub-id><pub-id pub-id-type="pmid">35592114</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00252"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosoyamada</surname><given-names>M.</given-names></name>
<name><surname>Takiue</surname><given-names>Y.</given-names></name>
<name><surname>Shibasaki</surname><given-names>T.</given-names></name>
<name><surname>Saito</surname><given-names>H.</given-names></name>
</person-group><article-title>The effect of testosterone upon the urate reabsorptive transport system in mouse kidney</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2010</year><volume>29</volume><fpage>574</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1080/15257770.2010.494651</pub-id><pub-id pub-id-type="pmid">20589576</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00252"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takiue</surname><given-names>Y.</given-names></name>
<name><surname>Hosoyamada</surname><given-names>M.</given-names></name>
<name><surname>Kimura</surname><given-names>M.</given-names></name>
<name><surname>Saito</surname><given-names>H.</given-names></name>
</person-group><article-title>The effect of female hormones upon urate transport systems in the mouse kidney</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2011</year><volume>30</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1080/15257770.2010.551645</pub-id><pub-id pub-id-type="pmid">21360409</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00252"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Felmlee</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Effect of Sex and Cross-Sex Hormone Treatment on Renal Monocarboxylate-Transporter Expression in Rats</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2404</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15102404</pub-id><pub-id pub-id-type="pmid">37896164</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00252"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuochi</surname><given-names>S.</given-names></name>
<name><surname>Galasso</surname><given-names>M.E.</given-names></name>
<name><surname>Colombo</surname><given-names>R.</given-names></name>
<name><surname>Giaquinto</surname><given-names>D.</given-names></name>
<name><surname>De Girolamo</surname><given-names>P.</given-names></name>
<name><surname>D'Angelo</surname><given-names>L.</given-names></name>
</person-group><article-title>Puberty onset curve in CD (Sprague Dawley) and Long Evans outbred male rats</article-title><source>Lab. Anim.</source><year>2022</year><volume>56</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1177/00236772221078725</pub-id><pub-id pub-id-type="pmid">35253499</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00252"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sengupta</surname><given-names>P.</given-names></name>
</person-group><article-title>The Laboratory Rat: Relating Its Age With Human's</article-title><source>Int. J. Prev. Med.</source><year>2013</year><volume>4</volume><fpage>624</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">23930179</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00252"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cora</surname><given-names>M.C.</given-names></name>
<name><surname>Kooistra</surname><given-names>L.</given-names></name>
<name><surname>Travlos</surname><given-names>G.</given-names></name>
</person-group><article-title>Vaginal Cytology of the Laboratory Rat and Mouse: Review and Criteria for the Staging of the Estrous Cycle Using Stained Vaginal Smears</article-title><source>Toxicol. Pathol.</source><year>2015</year><volume>43</volume><fpage>776</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1177/0192623315570339</pub-id><pub-id pub-id-type="pmid">25739587</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00252"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>J.</given-names></name>
<name><surname>Ng</surname><given-names>M.</given-names></name>
<name><surname>Felmlee</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Sex Hormones Regulate Rat Hepatic Monocarboxylate Transporter Expression and Membrane Trafficking</article-title><source>J. Pharm. Pharm. Sci.</source><year>2017</year><volume>20</volume><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.18433/J3CH29</pub-id><pub-id pub-id-type="pmid">29249221</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00252"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Juck</surname><given-names>M.</given-names></name>
<name><surname>Long</surname><given-names>W.</given-names></name>
</person-group><source>Determination of Hormones in Serum by LC/MS/MS Using Agilent Bond Elut Plexa SPE</source><publisher-name>Agilent Technologies</publisher-name><publisher-loc>Santa Clara, CA, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B22-pharmaceutics-17-00252"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Wei</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>A.</given-names></name>
<name><surname>Felmlee</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Sex and Cross-Sex Testosterone Treatment Alters Gamma-Hydroxybutyrate Acid Toxicokinetics and Toxicodynamics in Rats</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>143</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16010143</pub-id><pub-id pub-id-type="pmid">38276513</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00252"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asada</surname><given-names>K.</given-names></name>
<name><surname>Miyamoto</surname><given-names>K.</given-names></name>
<name><surname>Fukutomi</surname><given-names>T.</given-names></name>
<name><surname>Tsuda</surname><given-names>H.</given-names></name>
<name><surname>Yagi</surname><given-names>Y.</given-names></name>
<name><surname>Wakazono</surname><given-names>K.</given-names></name>
<name><surname>Oishi</surname><given-names>S.</given-names></name>
<name><surname>Fukui</surname><given-names>H.</given-names></name>
<name><surname>Sugimura</surname><given-names>T.</given-names></name>
<name><surname>Ushijima</surname><given-names>T.</given-names></name>
</person-group><article-title>Reduced expression of GNA11 and silencing of MCT1 in human breast cancers</article-title><source>Oncology</source><year>2003</year><volume>64</volume><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1159/000070297</pub-id><pub-id pub-id-type="pmid">12759536</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00252"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Kaushal</surname><given-names>A.</given-names></name>
<name><surname>Rezwan</surname><given-names>F.I.</given-names></name>
<name><surname>Kadalayil</surname><given-names>L.</given-names></name>
<name><surname>Karmaus</surname><given-names>W.</given-names></name>
<name><surname>Henderson</surname><given-names>A.J.</given-names></name>
<name><surname>Relton</surname><given-names>C.L.</given-names></name>
<name><surname>Ring</surname><given-names>S.</given-names></name>
<name><surname>Arshad</surname><given-names>S.H.</given-names></name>
<etal/>
</person-group><article-title>Changes in DNA methylation from pre- to post-adolescence are associated with pubertal exposures</article-title><source>Clin. Epigenetics</source><year>2019</year><volume>11</volume><fpage>176</fpage><pub-id pub-id-type="doi">10.1186/s13148-019-0780-4</pub-id><pub-id pub-id-type="pmid">31791392</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00252"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campesi</surname><given-names>I.</given-names></name>
<name><surname>Sanna</surname><given-names>M.</given-names></name>
<name><surname>Zinellu</surname><given-names>A.</given-names></name>
<name><surname>Carru</surname><given-names>C.</given-names></name>
<name><surname>Rubattu</surname><given-names>L.</given-names></name>
<name><surname>Bulzomi</surname><given-names>P.</given-names></name>
<name><surname>Seghieri</surname><given-names>G.</given-names></name>
<name><surname>Tonolo</surname><given-names>G.</given-names></name>
<name><surname>Palermo</surname><given-names>M.</given-names></name>
<name><surname>Rosano</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Oral contraceptives modify DNA methylation and monocyte-derived macrophage function</article-title><source>Biol. Sex. Differ.</source><year>2012</year><volume>3</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/2042-6410-3-4</pub-id><pub-id pub-id-type="pmid">22284681</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00252-g001"><label>Figure 1</label><caption><p>Kidney MCT1 membrane expression in OVX and CST Sprague&#x02013;Dawley rats administered sex hormones or their respective placebo controls. Results compared to male and female controls. OVX (<bold>A</bold>) and CST (<bold>B</bold>) rats administered 17&#x003b2;-estradiol; OVX (<bold>C</bold>) and CST (<bold>D</bold>) rats administered progesterone; OVX (<bold>E</bold>) and CST (<bold>F</bold>) rats administered an estrogen and progesterone combination; OVX (<bold>G</bold>) and CST (<bold>H</bold>) rats administered testosterone. Results presented as mean &#x000b1; SD with individual data points, N = 6. <sup>a</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to Male.</p></caption><graphic xlink:href="pharmaceutics-17-00252-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00252-g002"><label>Figure 2</label><caption><p>Kidney CD147 membrane expression in OVX and CST Sprague&#x02013;Dawley rats administered sex hormones or respective placebo controls. Results compared to male and female controls. OVX (<bold>A</bold>) and CST (<bold>B</bold>) rats administered 17&#x003b2;-estradiol; OVX (<bold>C</bold>) and CST (<bold>D</bold>) rats administered progesterone; OVX (<bold>E</bold>) and CST (<bold>F</bold>) rats administered an estrogen and progesterone combination; OVX (<bold>G</bold>) and CST (<bold>H</bold>) rats administered testosterone. Results presented as mean &#x000b1; SD with individual data points, N = 6. <sup>a</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to Male. <sup>b</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to Female. <sup>c</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to OVX Estrogen Placebo. <sup>d</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to OVX Testosterone Placebo. <sup>e</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to CST Testosterone Placebo.</p></caption><graphic xlink:href="pharmaceutics-17-00252-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00252-g003"><label>Figure 3</label><caption><p>Kidney SMCT1 membrane expression in OVX and CST Sprague&#x02013;Dawley rats administered sex hormones or respective placebo controls. Results compared to male and female controls. OVX (<bold>A</bold>) and CST (<bold>B</bold>) rats administered 17&#x003b2;-estradiol; OVX (<bold>C</bold>) and CST (<bold>D</bold>) rats administered progesterone; OVX (<bold>E</bold>) and CST (<bold>F</bold>) rats administered estrogen and progesterone combination; OVX (<bold>G</bold>) and CST (<bold>H</bold>) rats administered testosterone. Results presented as mean &#x000b1; SD with individual data points, N = 6. <sup>a</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to Male. <sup>b</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to Female. <sup>d</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to OVX Testosterone Placebo. <sup>e</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.05 compared to CST Testosterone Placebo.</p></caption><graphic xlink:href="pharmaceutics-17-00252-g003" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00252-t001"><object-id pub-id-type="pii">pharmaceutics-17-00252-t001_Table 1</object-id><label>Table 1</label><caption><p>Plasma 17&#x003b2;-Estradiol, progesterone, and testosterone concentrations in hormone- or placebo-treated OVX and CST rats, and female and male controls. Data presented as mean &#x000b1; SD, N = 6.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Plasma Hormone <break/>Concentration</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">17&#x003b2;-Estradiol <break/>(pg/mL)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">17&#x003b2;-Estradiol <break/>Non-Detected</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Progesterone <break/>(ng/mL)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Progesterone <break/>Non-Detected</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Testosterone <break/>(ng/mL)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Testosterone <break/>Non-Detected</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Estrogen Placebo</td><td align="left" valign="middle" rowspan="1" colspan="1">8.94 &#x000b1; 6.495</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">3.813 &#x000b1; 3.605</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Estrogen </td><td align="left" valign="middle" rowspan="1" colspan="1">1199 &#x000b1; 490.1</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">4.368 &#x000b1; 4.676</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Progesterone Placebo</td><td align="left" valign="middle" rowspan="1" colspan="1">7.769 &#x000b1; 2.163</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">2.106 &#x000b1; 1.762</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Progesterone</td><td align="left" valign="middle" rowspan="1" colspan="1">9.988 &#x000b1; 7.323</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">7.596 &#x000b1; 5.313</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Combo Placebo</td><td align="left" valign="middle" rowspan="1" colspan="1">14.28 &#x000b1; 9.546</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.969 &#x000b1; 1.154</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Combo</td><td align="left" valign="middle" rowspan="1" colspan="1">1023 &#x000b1; 552.2</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">11.36 &#x000b1; 4.661</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Testosterone Placebo</td><td align="left" valign="middle" rowspan="1" colspan="1">8.187 &#x000b1; 4.758</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">2.201 &#x000b1; 1.376</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVX Testosterone</td><td align="left" valign="middle" rowspan="1" colspan="1">9.155 &#x000b1; 1.556</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.033 &#x000b1; 0.5029</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">6.01 &#x000b1; 2.237</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female (Estrus)</td><td align="left" valign="middle" rowspan="1" colspan="1">20.97 &#x000b1; 14.65</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">8.026 &#x000b1; 2.4</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Estrogen Placebo </td><td align="left" valign="middle" rowspan="1" colspan="1">5.899 &#x000b1; 4.138</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.363 &#x000b1; 0.5882</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Estrogen</td><td align="left" valign="middle" rowspan="1" colspan="1">1159 &#x000b1; 414.3</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">2.839 &#x000b1; 2.553</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Progesterone Placebo</td><td align="left" valign="middle" rowspan="1" colspan="1">13.51 &#x000b1; 4.177 </td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.296 &#x000b1; 0.7488</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Progesterone</td><td align="left" valign="middle" rowspan="1" colspan="1">10.33 &#x000b1; 4.506</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">6.661 &#x000b1; 4.244</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Combo Placebo</td><td align="left" valign="middle" rowspan="1" colspan="1">6.126 &#x000b1; 4.356</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.481 &#x000b1; 0.8062</td><td align="left" valign="middle" rowspan="1" colspan="1">1 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Combo</td><td align="left" valign="middle" rowspan="1" colspan="1">1447 &#x000b1; 534.9</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">8.665 &#x000b1; 4.866</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Testosterone Placebo</td><td align="left" valign="middle" rowspan="1" colspan="1">6.522 &#x000b1; 2.987</td><td align="left" valign="middle" rowspan="1" colspan="1">1 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.414 &#x000b1; 0.948</td><td align="left" valign="middle" rowspan="1" colspan="1">1 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1">6 out of 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CST Testosterone</td><td align="left" valign="middle" rowspan="1" colspan="1">33.52 &#x000b1; 12.38</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.899 &#x000b1; 1.442</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" rowspan="1" colspan="1">5.832 &#x000b1; 1.8</td><td align="left" valign="middle" rowspan="1" colspan="1">0 out of 6</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.2 &#x000b1; 5.654</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 out of 6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.791 &#x000b1; 1.832</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 out of 6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.099 &#x000b1; 0.4514</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 out of 6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00252-t002"><object-id pub-id-type="pii">pharmaceutics-17-00252-t002_Table 2</object-id><label>Table 2</label><caption><p>Percentage change in kidney MCT1, CD147, and SMCT1 expression following sex and cross-sex hormone treatment in OVX and CST rats, and in females relative to males. N = 6 per treatment group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment vs. Placebo</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MCT1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD147</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SMCT1</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">OVX</td><td align="center" valign="middle" rowspan="1" colspan="1">17&#x003b2;-estradiol </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;42.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;62</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Progesterone </td><td align="center" valign="middle" rowspan="1" colspan="1">177.3</td><td align="center" valign="middle" rowspan="1" colspan="1">159.7</td><td align="center" valign="middle" rowspan="1" colspan="1">56.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17&#x003b2;-estradiol/Progesterone</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;79.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;32.5</td><td align="center" valign="middle" rowspan="1" colspan="1">39.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Testosterone </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">137.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">423.8</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CST</td><td align="center" valign="middle" rowspan="1" colspan="1">17&#x003b2;-estradiol</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;43.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;22.2</td><td align="center" valign="middle" rowspan="1" colspan="1">70.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Progesterone </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;29.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;20</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;45.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17&#x003b2;-estradiol/Progesterone</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;39.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;38.5</td><td align="center" valign="middle" rowspan="1" colspan="1">56.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Testosterone </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">524.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">332.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246.4</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Female vs. Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;53.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">133.4</td></tr></tbody></table></table-wrap></floats-group></article>